JPRN-UMIN000006249已完成2 期
Randomized Phase II clinical trial of personalized peptide vaccination with low dose of cyclophosphamide for standard therapy failer Biliary cancer patients. - Randomized Phase II clinical of personalized peptide vaccination for standard therapy failed Biliary cancer.
Kurume University Cancer Vaccine Center0 个研究点目标入组 44 人开始时间: 2011年8月30日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The following patients must be excluded. 1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 2) Patients with the past history of severe allergic reactions. 3) (Females) Patients who are during pregnancy, lactation expectant, and desiring future fertility. (Males) Patients do not accept contraception during the 1st vaccination to 70 days after the last vaccination." 4) Patients who are judged inappropriate for the clinical trial by doctors. 5)Active double cancer (synchronous double cancer and metachronous double cancer within 5 disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment.
研究者
相似试验
已完成
2 期
A phase II randomized clinical trial of personalized peptide vaccination in combination with Japanese herbal medicines for castration-resistant prostate cancer (CRPC)Castration-resistant prostate cancerJPRN-UMIN000010290Kurume University School of medicine, Department of Immunology and Immunotherapy70
已完成
2 期
Randomized Phase II clinical trial of personalized peptide vaccination for HCV positive patients with advanced liver cancer.liver cancerJPRN-UMIN000003520Kurume University Research Center for Innovative Cancer Therapy, Clinical Research Division84
已完成
2 期
Randomized Phase II clinical trial of personalized peptide vaccination for patients with advanced (stage IIIB/IV) or recurrence non-small cell lung cancer who had chemotheraphy of 1 or 2 regimen, to evaluate the progression free survial of docetaxel plus placebo versus docetaxel plus pesonalized pepitide vaccine.non-small cell lung cancerJPRN-UMIN000003521Kurume University Research Center for Innovative Cancer Therapy, Clinical Research Division64
已完成
2 期
Phase II randomised clinical trial of personalized peptide vaccination in combination with Dai-kenchu-to for colorectal cancer patients resistant to standard therapies.colorectal cancerJPRN-UMIN000008126Kurume University Cancer Vaccine Center60
已完成
2 期
Phase II randomised clinical trial of personalized peptide vaccination in combination with Ninjin-yoei-to for lung cancer patients resistant to standard therapies .lung cancerJPRN-UMIN000008940Kurume University Cancer Vaccine Center80